Alnylam Pharmaceuticals is an early-stage therapeutics company. The Cambridge, Massachusetts-based company was founded in 2002 by Polaris Venture Partners, Cardinal Partners, and an international group of scientists that discovered key aspects of the novel biological phenomenon of RNA interference.Alnylam's therapeutics focus on a wide array of human diseases that are not adequately addressed by current therapeutic approaches.